D. Boral Capital Reiterates “Buy” Rating for VolitionRx (NYSE:VNRX)

VolitionRx (NYSE:VNRX)‘s stock had its “buy” rating reissued by equities researchers at D. Boral Capital in a research report issued on Wednesday,Benzinga reports. They presently have a $5.00 price target on the stock.

Several other brokerages have also recently issued reports on VNRX. Benchmark reaffirmed a “hold” rating on shares of VolitionRx in a research note on Friday, November 22nd. StockNews.com began coverage on shares of VolitionRx in a research report on Tuesday. They issued a “sell” rating for the company.

VolitionRx Price Performance

Shares of VolitionRx stock traded down $0.01 on Wednesday, hitting $0.65. The company had a trading volume of 29,923 shares, compared to its average volume of 83,660. VolitionRx has a 52 week low of $0.43 and a 52 week high of $1.23. The company has a market cap of $60.23 million, a PE ratio of -1.81 and a beta of 1.20. The business has a 50-day simple moving average of $0.65 and a 200-day simple moving average of $0.66.

Insider Activity at VolitionRx

In other VolitionRx news, CEO Cameron John Reynolds purchased 139,811 shares of the business’s stock in a transaction dated Monday, December 9th. The shares were acquired at an average price of $0.57 per share, for a total transaction of $79,692.27. Following the acquisition, the chief executive officer now owns 2,117,404 shares of the company’s stock, valued at $1,206,920.28. This trade represents a 7.07 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Guy Archibald Innes acquired 174,764 shares of the firm’s stock in a transaction that occurred on Monday, December 9th. The stock was acquired at an average price of $0.57 per share, with a total value of $99,615.48. Following the completion of the acquisition, the director now directly owns 617,085 shares of the company’s stock, valued at $351,738.45. This represents a 39.51 % increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders have purchased 358,266 shares of company stock valued at $204,212. Corporate insiders own 12.80% of the company’s stock.

Institutional Investors Weigh In On VolitionRx

A hedge fund recently raised its stake in VolitionRx stock. Ground Swell Capital LLC boosted its position in shares of VolitionRx Limited (NYSE:VNRX) by 78.8% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 45,959 shares of the company’s stock after purchasing an additional 20,249 shares during the period. Ground Swell Capital LLC’s holdings in VolitionRx were worth $28,000 at the end of the most recent quarter. 8.09% of the stock is owned by institutional investors and hedge funds.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.